- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Septerna, Inc. Common Stock(SEPN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SEPN
11/13/2026: SEPN (5-star) is a REGULAR-BUY. BUY for 14 days. Simulated Profits (-3.49%). Updated daily EoD!
Septerna, Inc. is a clinical-stage biotechnology company focused on developing oral small molecule drugs targeting GPCRs via its proprietary Native Complex platform. Its main strength lies in a unique scientific approach that seeks to tackle historically difficult biological targets, potentially offering a major improvement over existing injectable treatments. The primary investment story centers on the success of its lead program, SEP-786, and the scalability of its discovery platform. However, as an early-stage company, it faces significant risks including clinical trial uncertainty and heavy reliance on future capital infusions. The stock may suit growth-oriented investors with high risk tolerance who are looking for exposure to novel drug discovery.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical success but carries extreme binary risk. |
| Momentum investor | Mixed fit | Momentum may track clinical trial news, but the stock lacks the trading history required for consistent signals. |
| Value investor | Weak fit | There are no earnings or cash flows to support a traditional value-based investment thesis. |
| Dividend investor | Weak fit | The company does not pay a dividend and is unlikely to do so in the near future. |
| Low-risk investor | Weak fit | Biotechnology development carries high volatility and the potential for total loss of capital. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause significant, rapid shifts in stock valuation. |
| Valuation risk | High | Valuations are speculative and rely heavily on future, unproven clinical outcomes. |
| Competition risk | Medium / high | Established players in the GPCR space may develop superior or faster-to-market solutions. |
| Business quality | Medium | The company relies on a single proprietary platform to drive value, concentrating R&D risk. |
| Dividend income | Low / none | The business model prioritizes cash burn for R&D over shareholder distributions. |
| Execution risk | High | The ability to successfully navigate clinical and regulatory pathways is uncertain. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.03B USD | Price to earnings Ratio - | 1Y Target Price 59.22 |
Price to earnings Ratio - | 1Y Target Price 59.22 | ||
Volume (30-day avg) 433.2K shares | Beta 2.2 | 52 Weeks Range 21.31 - 53.34 | Updated Date 11/14/2026 |
52 Weeks Range 21.31 - 53.34 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 91.32% | Avg. Invested days 39 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Research and development of GPCR-targeting oral small molecules. | The company currently makes no revenue; it survives on capital raised to fund future drug prospects. |
Valuation
Trailing PE - | Forward PE 107.53 | Enterprise Value 1.53B | Price to Sales(TTM) 21.04 |
Enterprise Value 1.53B | Price to Sales(TTM) 21.04 | ||
Enterprise Value to Revenue 15.91 | Enterprise Value to EBITDA - | Shares Outstanding 47.55M | Shares Floating 27.28M |
Shares Outstanding 47.55M | Shares Floating 27.28M | ||
Percent Insiders 2.89 | Percent Institutions 100.08 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

